Allergen‐specific immunotherapy enhances CD8+ CD25+ CD137+ regulatory T cells and decreases nasal nitric oxide

• Published in: Pediatric allergy and immunology Vol. 30; no. 5; pp. 531 - 539
• Main Authors: Tsai, Yi‐Giien, Yang, Kuender D., Wen, Yung‐Sung, Hung, Chih‐Hsing, Chien, Jien‐Wen, Lin, Ching‐Yuang, Kalaycı, Ömer
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.08.2019
• Subjects: Adjuvants, Immunologic - pharmacology; Adolescent; Allergens; Allergic rhinitis; Allergies; allergy; Animals; Antigens, Dermatophagoides - immunology; CD137; CD137 antigen; CD25 antigen; CD4 antigen; CD8 antigen; CD8 Antigens - metabolism; Cell Proliferation; Cells, Cultured; Child; Contact inhibition; Dermatophagoides pteronyssinus - immunology; Desensitization, Immunologic - methods; Enzyme-linked immunosorbent assay; Epithelial cells; Female; Flow cytometry; Forkhead Transcription Factors - genetics; Forkhead Transcription Factors - metabolism; Foxp3 protein; Humans; Hypersensitivity; Hypersensitivity - immunology; Hypersensitivity - therapy; Immunoregulation; Immunotherapy; Inflammation; Interleukin-2 Receptor alpha Subunit - metabolism; Lipopeptides - pharmacology; Lymphocytes; Lymphocytes T; Male; Mucosa; Nitric oxide; Nitric Oxide - analysis; Nitric-oxide synthase; Nose; regulatory T cells; RNA, Small Interfering - genetics; T-Lymphocytes, Regulatory - immunology; TLR2 protein; Toll-Like Receptor 2 - agonists; Toll-like receptors; Toll‐like receptor 2; Tumor Necrosis Factor Receptor Superfamily, Member 9 - genetics; Tumor Necrosis Factor Receptor Superfamily, Member 9 - metabolism; Tumor necrosis factor receptors; Western blotting; regulatory T cells; allergy; CD137; Toll-like receptor 2; immunotherapy
• ISSN: 0905-6157; 1399-3038; 1399-3038
• DOI: 10.1111/pai.13061

Background 4‐1BB (CD137), a member of the inducible tumor necrosis factor receptor (TNFR) family, is expressed on regulatory T (Treg) cells and regulates Treg cells to control allergic inflammation. Pam3CSK4, a synthetic TLR2 ligand that can expand CD8+ Treg function, is a promising adjuvant for all...